Threshold Pharmaceuticals, Inc (THLD): Opiniones

7,32 en re market.... a ver si tira mas pa arriba!!

Threshol Pharmaceuticals, Inc (THLD)

Veras el 8.88 como se lo revientan

8.888889888888888888888888888888 above and beyond:)

03/16/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced the European Commission has granted Orphan Drug Designation for TH-302, a hypoxia-targeted drug, for the treatment of soft tissue sarcoma.

"Receiving orphan designation for TH-302 in soft tissue sarcoma in the European Union (EU) is an important achievement for Threshold," said Barry Selick, Ph.D., CEO of Threshold. "Soft tissue sarcoma is an aggressive form of cancer for which there is a significant unmet medical need. TH-302 was designed to selectively target hypoxic regions within tumors, which are believed to not be effectively treated with current therapy. The Orphan Drug Designation was granted as early studies of TH-302 have shown that it might be of significant benefit for patients with soft tissue sarcoma when combined with doxorubicin."

Threshold Pharmaceuticals is currently conducting a pivotal Phase 3 study in soft tissue sarcoma comparing TH-302 in combination with doxorubicin against single agent doxorubicin. The same combination regimen of TH-302 with doxorubicin was investigated in the single-arm Phase 2 (TH-CR-403) study. Data from this Phase 2 study were most recently presented at the Connective Tissue Oncology Society (CTOS) meeting in October of 2011. In February 2011, Threshold Pharmaceuticals announced that it had reached agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment for the Phase 3 study (TH-CR-406) which includes a primary efficacy endpoint of overall survival. The international, randomized, controlled Phase 3 clinical trial was initiated in September 2011, and is being conducted in partnership with the Sarcoma Alliance for Research through Collaboration (SARC). The trial is designed to enroll 450 patients with metastatic or locally advanced unresectable soft tissue sarcoma.

Zeltia lo que pudiste ser...y ahora THLD te pasa como una moto...lo siento sr.Sousa.

No quedan acciones.

El que quiera comprar tiene que barrer o esperar al juicio final:)

Buenoooooo!

Ojito, que lo mismo se superan ya los maximos historicos en preapertura! Lo mismo luego se desinfla, pero al paso que vamos igual tenemos otro dia con un +20%...

Llevo varios días siguiendo este tema, y he tenido muchas ganas de entrar en THLD, pero no tengo liquides. Tengo Commerzbank con unas perdidas de unos 100 € y estas no se mueven. No se si sera tarde para desacerme de estas y engancharme a THLD o ya voy tarde?
Alguna recomendacion?

THLD ha tenido tres escalones en el último mes. Hoy, parece ser, veremos el cuarto. No es normal esta preapertura.

es dificil recomendar con el dinero de otros, te cuento lo que yo hice.
antes de ayer vendi santander con 550euros de perdidas y entre en THLD
llegue tarde? hombre lo ideal hubiera sido comprarlas en 1 dolar y pico, pero esta accion creo que todavia tiene recorrido, almenos mas que SAN que he tenido que aguantarlas 8 meses y soportar minisvalias de -25%